It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumor histology is an important predictor of therapeutic response and outcomes in lung cancer. Tissue sampling for pathologist review is the most reliable method for histology classification, however, recent advances in deep learning for medical image analysis allude to the utility of radiologic data in further describing disease characteristics and for risk stratification. In this study, we propose a radiomics approach to predicting non-small cell lung cancer (NSCLC) tumor histology from non-invasive standard-of-care computed tomography (CT) data. We trained and validated convolutional neural networks (CNNs) on a dataset comprising 311 early-stage NSCLC patients receiving surgical treatment at Massachusetts General Hospital (MGH), with a focus on the two most common histological types: adenocarcinoma (ADC) and Squamous Cell Carcinoma (SCC). The CNNs were able to predict tumor histology with an AUC of 0.71(p = 0.018). We also found that using machine learning classifiers such as k-nearest neighbors (kNN) and support vector machine (SVM) on CNN-derived quantitative radiomics features yielded comparable discriminative performance, with AUC of up to 0.71 (p = 0.017). Our best performing CNN functioned as a robust probabilistic classifier in heterogeneous test sets, with qualitatively interpretable visual explanations to its predictions. Deep learning based radiomics can identify histological phenotypes in lung cancer. It has the potential to augment existing approaches and serve as a corrective aid for diagnosticians.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mass General Brigham, Harvard Medical School, Artificial Intelligence in Medicine (AIM) Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)
2 Mass General Brigham, Harvard Medical School, Artificial Intelligence in Medicine (AIM) Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
3 Harvard T.H. Chan School of Public Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Massachusetts General Hospital, Division of Thoracic Surgery, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
5 Harvard T.H. Chan School of Public Health, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
6 Mass General Brigham, Harvard Medical School, Artificial Intelligence in Medicine (AIM) Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Dana Farber Cancer Institute and Brigham and Women’s Hospital, Department of Radiology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); CARIM & GROW, Maastricht University, Radiology and Nuclear Medicine, Maastricht, The Netherlands (GRID:grid.5012.6) (ISNI:0000 0001 0481 6099)